Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Pediatr Surg ; 46(8): 1490-4, 2011 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-21843713

RESUMO

BACKGROUND/PURPOSE: Necrotizing enterocolitis (NEC) is a major cause of mortality in neonates and is associated with a disruption in the protective intestinal barrier. The precise cause of NEC is elusive. However, ischemia/reperfusion injury of the intestine has been considered a major contributing factor. We examined the role of Y-27632, a selective Rho-kinase inhibitor, on a hypoxia/reoxygenation (H/R)-induced intestinal injury of newborn rat pups. METHODS: Hypoxia/reoxygenation was achieved by placing rat pups in an airtight chamber aerated with 95% N(2) + 5% CO(2) for 10 minutes followed by 10-minute 100% oxygen. Forty newborn rat pups were randomly allocated into 4 groups. Group 1 served as untreated controls. The pups in group 2 were subjected to H/R only. In groups 3 and 4, the rats were treated with intraperitoneal injection of 0.3 and 3 mg kg(-1) day(-1) of Y-27632 for 5 days following H/R, respectively. The pups were killed 6 days following the H/R injury. Intestine specimens were evaluated for histopathology and biochemical investigation. RESULTS: The microscopic lesions in H/R rat pups were virtually the same as those seen in neonatal NEC, with severe destruction of villi and crypts. Hypoxia/reoxygenation resulted in significant elevation in malondialdehyde levels, but decreased tissue nitric oxide levels (P < .05). Protective effects of Y-27632 on H/R-induced intestinal injury of newborn rat pups were observed with a significant decrease in the intestinal injury score, suppression in malondialdehyde levels, and increase in nitric oxide levels (P < .05). CONCLUSIONS: In this experimental study, Y-27632 significantly attenuated H/R-induced intestinal injury. These findings indicate that inhibition of Rho-kinase may offer a novel therapeutic approach in the treatment of NEC.


Assuntos
Amidas/farmacologia , Enterocolite Necrosante/tratamento farmacológico , Inibidores Enzimáticos/farmacologia , Hipóxia/complicações , Mucosa Intestinal/efeitos dos fármacos , Intestinos/efeitos dos fármacos , Piridinas/farmacologia , Amidas/administração & dosagem , Amidas/uso terapêutico , Animais , Dióxido de Carbono/administração & dosagem , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Esquema de Medicação , Enterocolite Necrosante/etiologia , Enterocolite Necrosante/metabolismo , Inibidores Enzimáticos/administração & dosagem , Inibidores Enzimáticos/uso terapêutico , Mucosa Intestinal/metabolismo , Mucosa Intestinal/patologia , Intestinos/patologia , Malondialdeído/metabolismo , Óxido Nítrico/metabolismo , Nitrogênio/administração & dosagem , Oxigênio/administração & dosagem , Piridinas/administração & dosagem , Piridinas/uso terapêutico , Distribuição Aleatória , Ratos , Ratos Wistar
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA